Poseida Therapeutics, Inc. (PSTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 9390 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:238,800214,600247,200282,500279,000142,557
Cash and cash equivalents25,50349,91140,14481,378164,80762,963
Short-term investments213,334164,695207,057201,115114,17879,594
Other undisclosed cash, cash equivalents, and short-term investments(37)(6)(1)715 
Receivables8,67211,9068,4379,08838,467232
Prepaid expense   4,517  
Other undisclosed current assets5,1923,6895,0592,4587,6625,330
Total current assets:252,664230,195260,696298,563325,129148,119
Noncurrent Assets
Operating lease, right-of-use asset22,57123,39624,20825,08527,00027,981
Property, plant and equipment20,38221,01122,11421,58621,74822,756
Intangible assets, net (including goodwill)5,5485,5485,5485,5485,5485,548
Goodwill4,2284,2284,2284,2284,2284,228
Intangible assets, net (excluding goodwill)1,3201,3201,3201,3201,3201,320
Other noncurrent assets1,0871,0651,0551,0551,0561,051
Total noncurrent assets:49,58851,02052,92553,27455,35257,336
TOTAL ASSETS:302,252281,215313,621351,837380,481205,455
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,93513,17013,28317,38821,90919,429
Employee-related liabilities7,5046,001
Accounts payable2,5422,0973,2002,2283,4263,661
Accrued liabilities12,39311,07310,08315,16010,9799,767
Deferred revenue44,81020,23320,09019,72316,7321,047
Other undisclosed current liabilities17,22816,48515,31716,77410,32719,617
Total current liabilities:76,97349,88848,69053,88548,96840,093
Noncurrent Liabilities
Long-term debt and lease obligation58,49158,40258,32258,25083,89684,868
Long-term debt, excluding current maturities58,49158,40258,32258,25058,16258,065
Liabilities, other than long-term debt43,12833,63245,05248,11527,31210,702
Deferred revenue18,7878,46119,06121,33325,2878,811
Deferred income tax liabilities    555555
Other liabilities2,4782,3552,2452,0911,9701,836
Operating lease, liability21,86322,81623,74624,63625,73426,803
Other undisclosed noncurrent liabilities  3,9923,9923,9923,9923,992
Total noncurrent liabilities:101,61996,026107,366110,357115,20099,562
Total liabilities:178,592145,914156,056164,242164,168139,655
Equity
Equity, attributable to parent123,660135,301157,565187,595216,31365,800
Common stock1099996
Additional paid in capital692,792672,736667,262658,596653,991573,878
Accumulated other comprehensive income (loss)(200)(280)2(149)(144)(132)
Accumulated deficit(568,942)(537,164)(509,708)(470,861)(437,543)(507,952)
Total equity:123,660135,301157,565187,595216,31365,800
TOTAL LIABILITIES AND EQUITY:302,252281,215313,621351,837380,481205,455

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues9,35220,01310,34310,051116,3062,700
Gross profit:9,35220,01310,34310,051116,3062,700
Operating expenses(45,574)(47,868)(49,859)(43,272)(44,526)(44,245)
Operating income (loss):(36,222)(27,855)(39,516)(33,221)71,780(41,545)
Nonoperating income
(Other Nonoperating income)
6,7872,5402,6972,17065652
Interest and debt expense(2,236)(2,141)(2,028)(1,975)(1,775)(1,543)
Income (loss) from continuing operations before income taxes:(31,671)(27,456)(38,847)(33,026)70,661(43,036)
Income tax expense (107)  (292)(252) 
Income (loss) from continuing operations:(31,778)(27,456)(38,847)(33,318)70,409(43,036)
Income (loss) before gain (loss) on sale of properties:70,409(43,036)
Net income (loss) available to common stockholders, basic:(31,778)(27,456)(38,847)(33,318)70,409(43,036)
Other undisclosed net income (loss) available to common stockholders, diluted    18,161(18,161) 
Net income (loss) available to common stockholders, diluted:(31,778)(27,456)(38,847)(15,157)52,248(43,036)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net income (loss):(31,778)(27,456)(38,847)(33,318)70,409(43,036)
Comprehensive income (loss):(31,778)(27,456)(38,847)(33,318)70,409(43,036)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent80(282)151(5)(12)(132)
Comprehensive income (loss), net of tax, attributable to parent:(31,698)(27,738)(38,696)(33,323)70,397(43,168)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: